Literature DB >> 18241530

Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRS.

Suzanne Holroyd1, Lillian J Currie, G Frederick Wooten.   

Abstract

OBJECTIVE: The unified Parkinson's disease rating scale (UPDRS) is the most widely used tool to rate the severity and the stage of Parkinson's disease (PD). However, the mentation, behavior and mood (MBM) subscale of the UPDRS has received little investigation regarding its validity and sensitivity. Three items of this subscale were compared to criterion tests to examine validity, sensitivity and specificity.
METHODS: Ninety-seven patients with idiopathic PD were assessed on the UPDRS. Scores on three items of the MBM subscale, intellectual impairment, thought disorder and depression, were compared to criterion tests, the telephone interview for cognition status (TICS), psychiatric assessment for psychosis and the geriatric depression scale (GDS). Non-parametric tests of association were performed to examine concurrent validity of the MBM items. The sensitivities, specificities and optimal cutoff scores for each MBM item were estimated by receiver operating characteristic (ROC) curve analysis.
RESULTS: The MBM items demonstrated low to moderate correlation with the criterion tests, and the sensitivity and specificity were not strong. Even using a score of 7.0 on the items of the MBM demonstrated a sensitivity/specificity of only 0.19/0.48 for intellectual impairment, 0.60/0.72 for thought disorder and 0.61/0.87 for depression. Using a more appropriate cutoff of 2.0 revealed sensitivities of 0.01, 0.38 and 0.13 respectively. DISCUSSION: The MBM subscale items of intellectual impairment, thought disorder and depression are not appropriate for screening or diagnostic purposes. Tools such as the TICS and the GDS should be considered instead.

Entities:  

Mesh:

Year:  2008        PMID: 18241530     DOI: 10.1179/016164107X251772

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  3 in total

1.  Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

Authors:  E Y Uc; M P McDermott; K S Marder; S W Anderson; I Litvan; P G Como; P Auinger; K L Chou; J C Growdon
Journal:  Neurology       Date:  2009-11-03       Impact factor: 9.910

2.  Homotaurine in Parkinson's disease.

Authors:  Lucia Ricciardi; Francesca De Nigris; Alessandro Specchia; Alfonso Fasano
Journal:  Neurol Sci       Date:  2015-04-19       Impact factor: 3.307

3.  Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study.

Authors:  Ann Liebert; Brian Bicknell; E-Liisa Laakso; Gillian Heller; Parastoo Jalilitabaei; Sharon Tilley; John Mitrofanis; Hosen Kiat
Journal:  BMC Neurol       Date:  2021-07-02       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.